



New Hampshire Medicaid Fee-for-Service Program

Prior Authorization Drug Approval Form

Calcitonin Gene-Related Peptide (CGRP) Inhibitors for Migraine and Cluster Headaches

DATE OF MEDICATION REQUEST: / /

PATIENT LAST NAME:

PATIENT FIRST NAME:

SECTION III: CLINICAL HISTORY (CONTINUED)

For prevention of migraine headaches, please answer questions 3–5.

3. Has medication overuse headache been ruled out by trial and failure of titrating off acute migraine treatments in the past? Yes No

4. On average, how many migraine days per month has the patient had for the past three months?

5. **For Nurtec® ODT or Qulipta™:** Has the patient tried and failed at least one injectable CGRP? Yes No

For prevention of cluster headaches, please answer questions 6–7.

6. Have other ICHD-III headaches been ruled out? Yes No

7. Has the patient tried and failed a one-month or longer trial of any two of the following oral medications **or** has the patient had a contraindication to any two of the following oral medications?

- suboccipital steroid injections
- lithium
- verapamil
- warfarin
- melatonin

If yes, please list treatment failures and provide dates:

(Form continues on the next page.)



New Hampshire Medicaid Fee-for-Service Program

Prior Authorization Drug Approval Form

Calcitonin Gene-Related Peptide (CGRP) Inhibitors for Migraine and Cluster Headaches

DATE OF MEDICATION REQUEST: / /

PATIENT LAST NAME:

PATIENT FIRST NAME:

SECTION III: CLINICAL HISTORY (CONTINUED)

For treatment of migraine headaches, please answer questions 8–10.

8. On average, how many migraine days per month has the patient had for the past 6 months?

9. Has the patient tried and failed one or more of the following:

Yes No

- non-steroidal anti-inflammatory drugs (NSAIDs)
- non-opioid analgesics
- acetaminophen
- caffeinated analgesic combination

If **yes**, please list the treatment failures and provide dates:

10. Has the patient tried and failed one or more preferred triptan?

Yes No

If yes, please list the treatment failures and provide dates:

SECTION IV: FOR RENEWALS ONLY

11. Has the patient demonstrated a significant decrease in the number, frequency, or intensity of headaches? Yes No

12. Has the patient had an overall improvement in function with therapy? Yes No

13. Has the patient experienced any unacceptable toxicity? Yes No

Provide any additional information that would help in the decision-making process. **If additional space is needed, please use another page.**

I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

PRESCRIBER'S SIGNATURE: **DATE:**

Phone: 1-866-675-7755

Fax: 1-888-603-7696

